Elijah Cummings Lower Drug Costs Now Act

SmithRx Announces $20 Million Series B Led by Venrock

Retrieved on: 
星期四, 三月 10, 2022
Technology, Insurance, Human Resources, Professional Services, Software, Practice Management, Health, Pharmaceutical, Data Management, Industry, Rockefeller, TPA, Twitter, Smith, PBM, Elijah Cummings Lower Drug Costs Now Act, Intel, Director, Genomics, Adoption, MD, Board, Founders Fund, Dollar Shave Club, Apple Inc., Patient, Novartis Gene Therapies, Technology, Gilead Sciences, Growth, Cloudflare, Pharmacy, CEO, Management, Risk management, Nest, Illumina, Venrock, SmithRx, Venrock, SMITHRX, VENROCK

SmithRx, a next-generation pharmacy benefits management company, today announced the closing of a $20 million series B financing round, following a year of record growth in which the company surpassed 1,100 employer clients.

Key Points: 
  • SmithRx, a next-generation pharmacy benefits management company, today announced the closing of a $20 million series B financing round, following a year of record growth in which the company surpassed 1,100 employer clients.
  • Venrock led the oversubscribed round and was joined by existing investors, including Founders Fund.
  • SmithRx is leading the next-generation of pharmacy benefits with a tech-forward approach that provides full control and transparency to its clients.
  • For more information, please visit Venrocks website at www.venrock.com and follow the firm on Twitter at @venrock.

Green Shield expands pharmacy focus with acquisitions of NKS Health and The Health Depot

Retrieved on: 
星期三, 三月 9, 2022
Industry, Multiple sclerosis, Green Shield Canada, GSH, Physician, Rheumatoid arthritis, Digital technology, GSA, Elijah Cummings Lower Drug Costs Now Act, EVP, Health, Heath, Pharmacy, Conditional sentence, Pharmaceutical Services Negotiating Committee, Entrepreneurship, Non-Insured Health Benefits, Diversified Specialty Institute Holdings, Inc., Patient, Telehealth, Pharmacist, Mental health, Stroke, GSC, Technology, Solution, Migraine, Growth, Degenerative disease, Insurance, History, Program, CEO, Healthcare, Hospital, Health insurance, Medicine

In light of the growth trend in digital health, the GSC group of companies is also acquiring The Health Depot , an emerging leader in digital pharmacy with expertise in chronic disease management.

Key Points: 
  • In light of the growth trend in digital health, the GSC group of companies is also acquiring The Health Depot , an emerging leader in digital pharmacy with expertise in chronic disease management.
  • About Green Shield Holdings Inc.
    Part of the Green Shield Canada (GSC) group of companies, Green Shield Holdings Inc. (GSH) is the primary company used to house health services and health & benefits administration subsidiaries.
  • Green Shield Holdings Inc. is itself a wholly-owned subsidiary of the not-for-profit Green Shield Association (GSA).
  • NKS Health is a specialty pharmaceutical services company focused on the handling and service of injectable, infused and biologic medications.

Deep 6 and Carle Partner to Deploy Artificial Intelligence in Clinical Trials

Retrieved on: 
星期二, 二月 22, 2022
Physician, Mask, Method, Growth, Elijah Cummings Lower Drug Costs Now Act, NLP, StartX, Natural language processing, Acceleration, Clinical trial, CA, Roger Hawkins (drummer), Pathology, Pancreatic cancer, Artificial intelligence, National, Patient, AI, National Cancer Institute, Research, CEO, Software, Medical device, Pharmaceutical industry, Techstars

Deep 6 AI's precision matching software is helping researchers find more, better-matching patients for their clinical studies significantly faster.

Key Points: 
  • Deep 6 AI's precision matching software is helping researchers find more, better-matching patients for their clinical studies significantly faster.
  • The leader in Clinical Trials Acceleration Software now collaborates with the Illinois-based Carle healthcare system to increase and diversify enrollment in clinical trials.
  • Carle physicians can also use the Deep 6 AI software to recommend targeted studies to eligible patients during their visits.
  • The company uses artificial intelligence (AI) and natural language processing (NLP) on structured and unstructured data, to precision match patients to clinical trials in minutes instead of months.

Lack of Transparency and Misaligned Incentives Reduce Adoption of Biosimilars Per National Alliance of Healthcare Purchaser Coalitions

Retrieved on: 
星期二, 二月 22, 2022
Health, The National Alliance, Twitter, Elijah Cummings Lower Drug Costs Now Act, Care, Taft–Hartley Act, Cost sharing, Adoption, National Alliance, LinkedIn, Multimedia, Science, Site, Traction, Patient, Union, Economics, Congress, Goal, CEO, Public sector, Health insurance, Generic drug

To help employers overcome these obstacles, the National Alliance of Healthcare Purchaser Coalitions (National Alliance) brought together seven regional coalitions and more than 60 employers for a series of roundtables across the country.

Key Points: 
  • To help employers overcome these obstacles, the National Alliance of Healthcare Purchaser Coalitions (National Alliance) brought together seven regional coalitions and more than 60 employers for a series of roundtables across the country.
  • "The US lags Europe in embracing and expanding the biosimilars market," said Michael Thompson, National Alliance president and CEO.
  • Engagement with employers and regional coalitions around biosimilars led by the National Alliance will continue this year.
  • The National Alliance of Healthcare Purchaser Coalitions (National Alliance) is the only nonprofit, purchaser-led organization with a national and regional structure dedicated to driving health and healthcare value across the country.

A Rare Report Card: NORD Grades All 50 States on Rare Disease Policy Issues

Retrieved on: 
星期二, 二月 22, 2022
Policy, Human, National Organization for Rare Disorders, Degenerative disease, Orphan Drug Act of 1983, COVID-19, Disease, Elijah Cummings Lower Drug Costs Now Act, Multimedia, State government, Patient, NORD, Legislation, State, Pharmaceutical industry, Health insurance, Online shopping, Medicaid

NORD's State Report Card Provides Critical Analysis Across Nine Policy Areas, Including Telehealth, Drug Costs and More

Key Points: 
  • NORD's State Report Card Provides Critical Analysis Across Nine Policy Areas, Including Telehealth, Drug Costs and More
    "NORD was founded in 1983 by individuals fighting for policy change against all odds.
  • We're proud to continue to identify ways the rare disease community can push their lawmakers to better support rare disease patients through the latest edition of our State Report Card," said Heidi Ross, Acting Vice President, Policy and Regulatory Affairs, NORD.
  • A total of 21 states have signed legislation into law creating a Rare Disease Advisory Council, including six in 2021 alone.
  • The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseasesinthe United States.

National Charitable Nonprofits Urge Prioritization of Pandemic and Workforce Shortage Relief

Retrieved on: 
星期二, 二月 15, 2022
Elijah Cummings Lower Drug Costs Now Act, State, WORK, Volunteering, Education, Public Service Loan Forgiveness, McConnell, Solution, Letter, Congress, Environment, Workforce, Administration, Universal, Policy, American Rescue Plan Act of 2021, Public health, McCarthy, Program, Face, Industry, Organization, Pharmaceutical industry, Management

Today, many charitable entities are experiencing unprecedented workforce shortages including 450,000 fewer employees than before the pandemic forcing them to restrict needed services, institute waiting lists, or close operations entirely.

Key Points: 
  • Today, many charitable entities are experiencing unprecedented workforce shortages including 450,000 fewer employees than before the pandemic forcing them to restrict needed services, institute waiting lists, or close operations entirely.
  • According to the letter: "The charitable nonprofit sector is the backbone of our communities.
  • We continue to face unprecedented challenges as we assist you and the American people in providing pandemic relief and economic recovery.
  • Specifically, nonprofits are seeking capacity building grants to assist in volunteer generation and management and relief for volunteer drivers.

Medical Oncology Associates of San Diego Joins OneOncology

Retrieved on: 
星期一, 二月 14, 2022
Patient, Cancer, CEO, Oncology Care Model, Pharmacy, Sharp HealthCare, SAN, Elijah Cummings Lower Drug Costs Now Act, Sharp Memorial Hospital, Technology, Oncology, LinkedIn, Insurance, Alvarado Hospital, Partnership, Physician, Association rule learning, Growth, Multimedia, Organization, Scripps Mercy Hospital, Medicine, Pharmaceutical industry, Health insurance, Medicare, MD

SAN DIEGO and NASHVILLE, Tenn., Feb. 14, 2022 /PRNewswire/ --Medical Oncology Associates of San Diego (MOASD) and OneOncology, the national platform for independent community oncology practices, today announced the two organizations have finalized agreements to become partners.

Key Points: 
  • SAN DIEGO and NASHVILLE, Tenn., Feb. 14, 2022 /PRNewswire/ --Medical Oncology Associates of San Diego (MOASD) and OneOncology, the national platform for independent community oncology practices, today announced the two organizations have finalized agreements to become partners.
  • Medical Oncology Associates of San Diego is the second California-based practice to join the platform.
  • Medical Oncology Associates of San Diego was founded by Fred Saleh, MD nearly 40 years ago.
  • OneOncology supports our platform of community oncology practices through group purchasing, operational optimization, practice growth, and clinical innovation.

Aphios Granted US Patent For Combination HIV Latency Nanoparticles Towards an HIV Cure

Retrieved on: 
星期二, 二月 8, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Pandemic, Growth, Patent, Factor X, HIV/AIDS, Bubonic plague, Neurological disorder, Nanoparticle, Protein kinase, Memory, US, HIV, AIDS, HDAC, Elijah Cummings Lower Drug Costs Now Act, Infection, Technology, Conditional sentence, Corporation, ARV, ART, Chromatin, Family, CEO, PKC, Therapy, Supply (economics), Cancer, HIV-1, Drug discovery, Cell, Protein kinase C, COVID-19, Pharmaceutical industry

The Aphios 11,234,932 patent is part of a family of patents for a combination of two Latency Reversal Agents (LRAs) -- a Protein Kinase C (PKC) modulator of the anti-tumor class, ‘Bryoids’ and a Histone Deacetylase (HDAC) inhibitor co-encapsulated in long-circulating pegylated nanoparticles to purge latent HIV from cellular reservoirs. These patents are for the nanoparticles, medications, their manufacturing and uses. The two LRAs act synergistically. Bryostatin-1 activates, via a classical PKC pathway, transcription factors such as NF-κB that binds HIV-1 promoters and regulates their transcription, while the HDAC inhibitors increase histone acetylation, relaxing (opening) chromatin and facilitating the transcription of HIV-1 genes.

Key Points: 
  • Aphios Corporation announced today that it has been granted US Patent No.
  • 11,234,932 for treating HIV latency towards an HIV cure.
  • HIV, however, establishes latent long-term infection in a small pool of memory CD4+ T (immune) and other cells, which contain integrated but transcriptionally silent HIV provirus.
  • There are no commercially available drugs for treating HIV latency and/or curing HIV.

RxSS Named NCPA Awarded Vendor for Pharmacy Transparency

Retrieved on: 
星期二, 一月 25, 2022
Prescription, Technology, NCPA, LinkedIn, Contact, Plasma protein binding, Pharmacy, Public sector, Elijah Cummings Lower Drug Costs Now Act, Solution, Industry, Contract, Twitter, Organization, Pharmaceutical industry, Health insurance

OVERLAND PARK, Kan., Jan. 25, 2022 /PRNewswire/ -- Rx Savings Solutions ("RxSS") today announced it has been named an awarded vendor for pharmacy transparency by the National Cooperative Purchasing Alliance (NCPA), a leading national government purchasing cooperative.

Key Points: 
  • OVERLAND PARK, Kan., Jan. 25, 2022 /PRNewswire/ -- Rx Savings Solutions ("RxSS") today announced it has been named an awarded vendor for pharmacy transparency by the National Cooperative Purchasing Alliance (NCPA), a leading national government purchasing cooperative.
  • NCPA is a leading national government purchasing cooperative working to reduce the cost of goods and services by leveraging the purchasing power of public agencies in all 50 states.
  • RxSS currently serves 17 million members, including nearly 50 Fortune 500 clients and more than twenty health plans.
  • "RxSS brings market-leading technology and a proven track record of helping organizations simplify the complex world of prescription drugs," said Mike Muscara of NCPA.

CMS Takes Action to Address Pharmacy DIR Clawbacks That Harm Specialty Patients and Pharmacies

Retrieved on: 
星期五, 一月 7, 2022
Pharmacy, Medicare, Contract, Policy, Pharmacy technician, CMS, DIR, PBM, Medicare Part D, Nursing, Pharmacist, Patient, United States Department of Health and Human Services, National Association, Human, Elijah Cummings Lower Drug Costs Now Act, Centers for Medicare & Medicaid Services, Cancer, Federal, Congress, Specialty pharmacy, Haemophilia, Data management, Efficiency, NASP, Administration, Sale, GLOBE, Processor register, Technology, Multiple sclerosis, Center for Medicare and Medicaid Innovation, Center, Leadership, Health insurance, Hospital, Health

National Association of Specialty Pharmacy President and CEO Sheila Arquette, RPh stated, For years, rising pharmacy DIR fees under Medicare Part D have been harming specialty patients who are living with life-altering and often times life-threatening medical conditions and the pharmacies that serve them.

Key Points: 
  • National Association of Specialty Pharmacy President and CEO Sheila Arquette, RPh stated, For years, rising pharmacy DIR fees under Medicare Part D have been harming specialty patients who are living with life-altering and often times life-threatening medical conditions and the pharmacies that serve them.
  • CMS has a real opportunity to reduce senior drug costs through pharmacy DIR reform, which has manipulated drug costs under Medicare Part D while directly hurting the specialty pharmacies that serve patients with conditions like multiple sclerosis, hemophilia, or cancer.
  • Reforming pharmacy DIR fees would reduce the amount seniors pay for their drugs when they receive them from a pharmacy.
  • We remain committed to working with CMS as it advances pharmacy DIR fee reform to ensure that reforms are transparent, fair and support specialty patients and the pharmacies that serve them.